*NOVO CFO:PRIME BASAL INSULIN IMPACT IN U.S. HAS ’BEEN REALISED’
*NOVO EXECUTIVES SPEAK TO ANALYSTS ON A CONFERENCE CALL
*NOVO CFO SAYS NEGATIVE PRICING ENVIRONMENT IS 2-3% BEYOND 2017
*NOVO SEES U.S. PRESSURE ON MONDERN INSULIN
*NOVO ALSO SEES U.S. PRESSURE ON HUMAN GROWTH HORMONES